Exelixis, Inc. (EXEL)

NASDAQ: EXEL · Real-Time Price · USD
37.26
+1.04 (2.87%)
At close: Aug 1, 2025, 4:00 PM
37.47
+0.21 (0.56%)
After-hours: Aug 1, 2025, 4:29 PM EDT
2.87%
Market Cap10.03B
Revenue (ttm)2.23B
Net Income (ttm)602.30M
Shares Out 269.20M
EPS (ttm)2.08
PE Ratio17.94
Forward PE14.22
Dividendn/a
Ex-Dividend Daten/a
Volume5,660,898
Open36.22
Previous Close36.22
Day's Range35.88 - 38.09
52-Week Range23.21 - 49.62
Beta0.28
AnalystsBuy
Price Target44.00 (+18.09%)
Earnings DateJul 28, 2025

About SPLK

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 7, 2000
Employees 1,147
Stock Exchange NASDAQ
Ticker Symbol EXEL
Full Company Profile

Financial Performance

In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.

Financial Statements

Analyst Summary

According to 21 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price target is $44.0, which is an increase of 18.09% from the latest price.

Price Target
$44.0
(18.09% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards

EXEL continues to grow cabozantinib revenues while advancing zanzalintinib, but recent trial updates have been mixed and market reaction muted. STELLAR-303 has produced a success for zanzalintinib alt...

1 day ago - Seeking Alpha

Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans

Exelixis Inc. EXEL on Monday reported its first quarter of 2025 adjusted earnings of 75 cents per share, compared to 85 cents a year ago, beating the consensus of 56 cents.

3 days ago - Benzinga

Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript

Exelixis, Inc. (NASDAQ:EXEL) Q2 2025 Earnings Conference Call July 28, 2025 5:00 PM ET Company Participants l - Corporate Participant Amy C. Peterson - Executive VP of Product Development & Medical A...

4 days ago - Seeking Alpha

Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2025, provided an update on progress toward achieving key corporate objective...

4 days ago - Business Wire

Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) for the treatme...

8 days ago - Business Wire

Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2025 financial results will be released on Monday, July 28, 2025 after the markets close. At 5:0...

18 days ago - Business Wire

Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment

Exelixis is a strong buy due to robust CABOMETYX sales growth, with Q1 2025 revenues up 36% year-over-year and raised full-year 2025 guidance. Positive phase 3 STELLAR-303 results for zanzalintinib pl...

5 weeks ago - Seeking Alpha

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars

On Sunday, Exelixis, Inc. EXEL revealed topline results from the STELLAR-303 phase 3 pivotal trial of zanzalintinib (100 mg) combined with atezolizumab.

5 weeks ago - Benzinga

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizu...

5 weeks ago - Business Wire

Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Pro...

6 weeks ago - Business Wire

Product Performance, Big Money Lift Exelixis

Shares of Exelixis, Inc. (EXEL), an oncology-focused biopharmaceutical firm, boosted by Big Money inflows.

2 months ago - FXEmpire

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either...

2 months ago - Business Wire

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May and June: TD Cow...

2 months ago - Business Wire

Exelixis: A Notable Quarter

Exelixis just delivered a strong Q1 beat, raised 2025 guidance, and continues to benefit from robust Cabometyx sales and share buybacks. The company is transitioning to zanzalintinib as its next flags...

2 months ago - Seeking Alpha

Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance

Exelixis Inc. EXEL reported adjusted earnings of 62 cents per share on Tuesday for the first quarter of 2025, compared to 17 cents a year ago, beating the consensus of 36 cents.

2 months ago - Benzinga

Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript

Exelixis, Inc. (NASDAQ:EXEL) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Morr...

2 months ago - Seeking Alpha

Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, Exelixi...

2 months ago - Business Wire

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives...

2 months ago - Business Wire

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities...

3 months ago - Business Wire

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00...

3 months ago - Business Wire

EXEL Industries: Second quarter 2024–2025 sales down 3.8%

Q2 2024–2025 revenue: -3.8% Businesses proved to be resilient in an uncertain economic context Q2 sales (January 2025–March 2025))   2023–2024 2024–2025 Change (reported) Change (LFL*) Reported Report...

3 months ago - GlobeNewsWire

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult an...

4 months ago - Business Wire

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AAC...

4 months ago - Business Wire

Exelixis Growth Continues with Big Money Boosts

Oncology company Exelixis, Inc. (EXEL) growing business, eyeing more.

4 months ago - FXEmpire

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 45th...

5 months ago - Business Wire